Abstract Insulin and glucose may influence cancer mortality via their proliferative and anti-apoptotic properties. Using longitudinal data from the nationally representative Third National Health and Nutrition Examination Survey (NHANES III; 1988-1994, with an average follow-up of 8.5 years to death, we evaluated markers of glucose and insulin metabolism, with cancer mortality, ascertained using death certificates or the National Death Index. Plasma glucose, insulin, C-peptide, and lipid concentrations were measured. Anthropometrics, lifestyle, medical, and demographic information was obtained during in-person interviews. After adjusting for age, race, sex, smoking status, physical activity, and body mass index, for every 50 mg/dl increase in plasma glucose, there was a 22% increased risk of overall cancer mortality. Insulin resistance was associated with a 41% (95% confidence interval (CI) (1.07-1.87; p = 0.01) increased risk of overall cancer mortality. These associations were stronger after excluding lung cancer deaths for insulin-resistant individuals (HR: 1.67; 95% CI: 1.15-2.42; p = 0.01), specifically among those with lower levels of physical activity (HR: 2.06; 95% CI: 1.4-3.0; p = 0.0001). Similar associations were observed for other blood markers of glucose and insulin, albeit not statistically significant. In conclusion, hyperglycemia and insulin resistance may be 'high-risk' conditions for cancer mortality. Managing these conditions may be effective cancer control tools.
Introduction
Cancer is the leading cause of death in individuals under the age of 85 years [1, 2] and overall, the second leading cause of death in the US, responsible for one in four deaths [3] . It has been hypothesized that insulin resistance (characterized by hyperinsulinemia) and hyperglycemia may play a role in tumor growth by providing a conducive environment for the growth of cancer cells (reviewed in [4] ). Hyperinsulinemia and hyperglycemia result from dysregulation of insulin action at the cellular level and insulin secretion (reviewed in [5] ). A major risk factor of this metabolic dysregulation is excess body weight (reviewed in [6] ), which has reached epidemic proportions in the US [7, 8] . It is noteworthy that excess adiposity accounts for approximately a quarter to one-third of cancers of the colon, breast, endometrium, kidney, and adenocarcinomas of the esophagus [9] . There is robust evidence from a large, national prospective study (n = 900.000) that obesity is associated with higher overall cancer and site-specific cancer mortality [10] . The authors estimated that a body mass index C25 contributed to about 90,000 cancer-related deaths in the US, annually. However, this study did not have the ability to investigate the potential underlying mechanisms that link obesity and cancer mortality due to the unavailability of laboratory data.
At first glance, hyperinsulinemia and hyperglycemia seem to be unrelated to cancer. However, some previous studies have evaluated diabetes or insulin resistance in relation to development of cancers. Taken together, these studies have generally found detrimental associations [11] [12] [13] [14] [15] and provide an impetus to further investigate these associations in human studies. Given that cancer is a major cause of death in the US [1, 2] , it is important to evaluate the impact of insulin and glucose on the late effects of cancer, in addition to its development.
Previous studies that address markers of glucose or insulin metabolism in relation to cancer morality did not have the ability to evaluate the confluence of multiple biomarkers and lifestyle [15] [16] [17] or relied on self-reported diabetes [18, 19] . Additionally, studies that utilized multiple biomarkers examined single cancer sites, specifically breast or colon cancer [20] [21] [22] . Furthermore, a recent large study assessed cancer mortality for men but not women [23] . Overall, the relationships of insulin resistance and diabetes as well as the insulin resistance syndrome (a constellation of related biochemical abnormalities, also known as the metabolic syndrome) in relation to cancer mortality are not well studied. With the recent increase in cancer prevalence and escalating rates of obesity, diabetes, and insulin resistance, studies examining the interrelationships of these conditions are required to ascertain whether managing these conditions along with lifestyle changes may serve as a tool for effective prevention of early death, in the very large at-risk population of cancer patients.
In the present study, we evaluated the longitudinal associations of obesity, hyperglycemia, measures of insulin resistance, and the insulin resistance syndrome in relation to overall cancer mortality, using data from the nationally representative National Health and Nutrition Examination Survey III (NHANES III) (1988) (1989) (1990) (1991) (1992) (1993) (1994) . We re-evaluated these relationships after excluding deaths from lung cancer (which is not associated with obesity). The availability of comprehensive data on medical history, diet, blood analyses, anthropometric measurements, and linkage with longitudinally ascertained mortality status of the participants made it possible to investigate these associations. Specifically, the presence of data on blood biomarkers related with insulin and glucose metabolism provides a unique opportunity to study potential mechanisms underlying cancer mortality. Additionally, self-reports of physical activity, an important risk factor of cancer, allowed us to explore how the relationships of cancer mortality and insulin resistance syndrome vary with this lifestyle behavior.
Methods

Study population
NHANES III, a nationally representative sample of the civilian non-institutionalized individuals, conducted by the National Center for Health Statistics of the Centers (NCHS) for Disease Control and Prevention in 1988-1994, was designed to provide detailed information on health and nutrition status of Americans. The NHANES III sample was selected through a complex, multistage probability design that allows results to be extrapolated to the entire US population [24] . NHANES III participants 17? years were eligible for mortality follow-up from the date of participation (1988-1994) through 31 December 2000. The present research included subjects aged 20-89 years, having sufficient data for at least three of five criteria for the insulin resistance syndrome. Individuals 20 years or older were considered young adults as per the NCEP-ATP III definition [25] . Pregnant women were excluded to avoid misclassification of body mass index (BMI) or insulin resistance syndrome. Subjects older than 89 years were excluded due to arbitrary assignment of a reported age of 90 years for confidentiality, which could result in inaccurate statistical adjustment for age in this group. The final analyses dataset consists of 15,594 individuals (Fig. 1) .
Data collection
The baseline survey consisted of a structured household interview and a standardized physical examination in a mobile examination center (MEC). Participant age, education level, race, alcohol use, current prescription medication and drug use including oral hypoglycemic agents and aspirin consumption, physical activity level, and presence of doctor-diagnosed medical conditions including hypertension were self-reported in a structured personal interview. Race-ethnic groups were categorized into four major ethnic groups: non-Hispanic whites, non-Hispanic blacks, Mexican-Americans, and ''other''. The ''other'' group included Aleut, Eskimo, American Indian, Asian, or Pacific Islander. These ethnic groups were defined based on combinations of the reported race and ethnicity responses of survey participants. History of diabetes was ascertained based on self-reported doctor-diagnosed diabetes and from questions querying insulin use or use of hypoglycemic agents. Blood pressure was measured by a physician; height, weight, and waist circumference were measured by trained personnel [24] . Body mass index was calculated from height and weight. Smoking status was computed as never, past, and current using self-reported responses during the in-person MEC interview to questions regarding use of cigarettes, pipes, and cigars, for the purpose of these analyses. The Household Adult Questionnaire queried 17 leisure time physical activities including type of activity and frequency in the past month. Estimated physical activity levels were obtained by multiplying each activity by its corresponding intensity value in metabolic equivalents (METS). These products were summed in order to produce an intensity-weighted frequency value for each participant for the current study.
During the physical examination, blood was obtained by venipuncture for all survey participants. The first venipunctures were done to collect fasting samples, with a median fasting time of *11 h. Blood lipids were measured using a Hitachi 704 Analyzer (Boehringer Mannheim Diagnostics). Fasting plasma glucose concentrations were measured using a modified hexokinase enzymatic method (Roche Cobas Mira). The oral glucose tolerance test (OGTT) was conducted on examinees between the ages of 40 and 74 years who did not use exogenous insulin. The OGTT protocol included two timed venipunctures and a glucose drink. After the first venipuncture, the examinee drank the glucose drink, and a second venipuncture was performed *2 h later. Insulin was analyzed using a radioimmunoassay, for adults 20? years, and C-peptide levels were obtained using the C-peptide radioimmunoassay (RIA) (Berthold MultiCrystal Gamma Counter, Berthold, Nashua, NH). Between 1991 and 1994, the procedure was modified to add tests for C-peptide and insulin on specimens from the second venipuncture. Examinees reporting a medical history of diabetes without the use of insulin therapy were eligible for the OGTT if their fasting values were normal. Glycosylated hemoglobin was measured using the Diamat Analyzer System (Bio-Rad Laboratories, Hercules, CA). Insulin-like growth factor-1 (IGF-1) concentrations were obtained only among participants who underwent a morning examination using the IGF-I ELISA assay (Webster, Texas). Details of the NHANES III protocols have been published [26] . Exposure definitions
Blood glucose
Three biomarkers of blood glucose metabolism were used: (1) fasting plasma glucose, (2) non-fasting plasma glucose following the OGTT, both of which are short-term indicators of blood glucose concentrations, and (3) glycosylated hemoglobin, which is a long-term indicator of blood glucose concentrations, over *3-4 months. A value of glycosylated hemoglobin below 6.0% is considered normal and above 7% indicates poor glycemic control [27] .
Insulin
Four biomarkers of insulin metabolism were used:
(1) Insulin resistance as per the Adult Treatment Panel (ATP) III, clinical diagnosis of insulin resistance is defined as elevated fasting glucose [110 mg/dl [25] . For the purpose of these analyses, individuals were also considered to be insulin resistant if they had self-reported current use of insulin or consumed oral hypoglycemic agents, which are insulin secretagogues as previously published [28] .
(2) Homeostatic Model Assessment (HOMA-IR): HOMA-IR is a technique that dually measures b-cell function and insulin resistance from basal glucose and insulin or C-peptide concentrations [29] . HOMA-IR was calculated using following equation: (fasting glucose (mg/ dl) 9 fasting insulin (lU/ml))/405). This technique compensates for variations in basal glucose levels [30] . A value of C2.8 better predicts the development of diabetes based on a previous study [31] .
(3) Serum Insulin: serum insulin is another potential marker for the measurement of insulin resistance with normal fasting levels ranging from 6 to 27 lU/ml [32] .
(4) C-peptide: C-peptide, a product of the enzymatic cleavage of pro-insulin, is a stable biomarker of pancreatic ß-cell secretory activity, with a half-life 2-5 times longer than insulin. In this study, fasting and postprandial C-peptide concentrations were utilized in addition to serum insulin concentrations to assess insulin resistance. The normal reference range for C-peptide levels is 0.24-0.72 pmol/ml [33] .
Insulin resistance syndrome
Data from the NHANES III adult questionnaires, MEC examination, and laboratory analysis were used to ascertain the presence of the insulin resistance syndrome. Insulin resistance syndrome, as detailed in the ATP III report [25] , was defined by the presence of three or more of the five criteria: (1) insulin resistance (fasting glucose C110 mg/ dl), (2) hypertension (systolic blood pressure C130 mm Hg or diastolic blood pressure C85 mm Hg), (3) hypertriglyceridemia (triglycerides C150 mg/dl), (4) low highdensity cholesterol levels (\40 mg/dl in men or \50 mg/dl in women), and (5) abdominal obesity (waist circumference [102 cm in men or[88 cm in women). For the purpose of these analyses, the ATP III definition was modified to classify individuals as insulin resistant if they self-reported current use of insulin or consumed oral hypoglycemic agents and was considered to be hypertensive if they reported use of anti-hypertensive drugs, as previously published [28] .
Body mass index
Body mass index was used as a continuous variable in the analysis. We repeated analyses after categorizing BMI according to the World Health Organization definitions with overweight defined as a BMI between 25.0 and 29.9 kg/m 2 and obesity defined as C30 kg/m 2 [34] .
Outcome
Cancer mortality ascertainment
Mortality information was based upon either (1) receipt of death certificates or (2) the results from a probabilistic match between NHANES III and the NCHS, National Death Index (NDI) records. The median length of followup was 8.55 years. The International Classification of Diseases, Tenth Revision (ICD-10; NCHS 2006) was used to identify deaths due to malignant neoplasm (ICD-10 codes C00-C97). The source of mortality data was the NDI. Persons who were not matched to a death record were considered alive at the end of the follow-up period. Additionally, data on the age and date of death of individual were available [35] .
Statistical methods
First, descriptive statistics was generated to evaluate risk factors, lifestyle, and dietary attributes related with cancer mortality and to identify potential confounders. Next, we used Cox proportional hazard regression analysis, using age as the time scale to compute the crude univariate relative hazard and 95% confidence intervals, of overall cancer mortality for the following exposures: plasma glucose (mg/dl; continuous), glycosylated hemoglobin (%, continuous), insulin resistance (yes/no), C-peptide (pmol/ml, continuous), insulin resistance syndrome (yes/no), and BMI (kg/m 2 ; continuous). Follow-up for those who died from causes other than cancer or those who were considered alive was censored at the age of death.
Confounders were defined as variables that changed the crude, age-adjusted hazard ratios for cancer mortality by 10% or more when entered singly into the regression models. Potential variables tested were age (continuous; years), race or ethnicity (categorical; white, black, Mexican, other), height (continuous; cm), cardiovascular disease (categorical yes/no), smoking (categorical; never, current, past), alcohol consumption (continuous; number of drinks), education (categorical; \12 and C12 years), cancer status at baseline (yes/no), use of oral hypoglycemic agents (yes/ no), and aspirin use (yes/no). Variables identified as confounders were added to the final multivariable Cox proportional regression models. Additionally, we also adjusted for variables shown to be associated with cancer mortality in previous literature [10, 36] . We tested for potential interactions of race, age, and gender for the relationships of insulin resistance and cancer mortality. The level of significance was set a priori at p = 0.10 to consider an interaction significant. A significance level of 0.05 was used for all the other tests. We reanalyzed the associations of all the exposures with cancer mortality after excluding lung cancer deaths, because lung cancer is not associated with obesity. All analyses were performed using SAS version 9.1 and SUDAAN version 10.
Results
Participant characteristics
The baseline characteristics of the NHANES III are summarized in Table 1 , which are expressed as either weighted frequencies or medians. The population had *77% nonHispanic whites and median age of 42 years. Approximately, half the population was obese or overweight (BMI [ 25) , and a median waist circumference of 91 cm. Twenty-two percent of the population had the insulin resistance syndrome defined as per the ATP III criteria, and 11.5% were insulin resistant. In this dataset, 525 persons (weighted frequency = 2.4% of the population) had died from cancer at the end of the follow-up period till 2000, with the highest deaths from lung cancer (n = 152 persons). A quarter of the patients who had died of cancer reported doctor-diagnosed cancer during their in-person baseline interview.
We evaluated correlations between anthropometric measurements (BMI and waist circumference) and the blood biomarkers, described in Table 1 . In summary, all the biomarkers were positively and significantly correlated with the anthropometric measures, and the coefficients ranged between 0.12 and 0.38 for both BMI and waist circumference. The correlation coefficient for fasting C-peptide with both the anthropometric measurements was 0.51-0.56. We observed a negative correlation between physical activity with both anthropometric measurements (r = -0.1 for BMI and waist circumference).
Associations of markers of insulin and glucose metabolism, and BMI with cancer mortality
Blood glucose
Fasting glucose The associations of plasma glucose concentrations and cancer mortality were evaluated by treating glucose as a continuous variable in the Cox proportional regression models. For every 50 mg/dl increase in fasting plasma glucose concentrations, the hazard ratio for mortality from all cancers combined increased by 22% after adjusting for age (HR: 1.22; 95% CI: 1.06-1.42) and 22% after adjusting for age, race, physical activity, smoking status, sex, and body mass index (HR: 1.22; 95% CI: 1.06-1.39). The increase in risk for cancer mortality persisted after excluding lung cancer deaths (HR: 1.25; 95% CI: 1.11-1.41). The associations of plasma glucose and cancer mortality were re-evaluated after excluding individuals who achieved glycemic control by using oral hypoglycemic agents or exogenous insulin (n = 949). The HRs for overall cancer mortality were [1 (HR: 1.05; 95% CI: 0.84-1.31). The associations were stronger after excluding lung cancer deaths (HR: 1.25 95% CI: 1.03-1.52) ( Table 2) .
In order to assess whether the observed detrimental associations persisted among individuals without a cancer diagnosis, we excluded persons with a self-reported history of cancer at baseline (n = 588) and reanalyzed these relationships. The direction of the associations remained unchanged among individuals with no history of cancer, after adjusting for age, sex, smoking status, physical activity, and body mass index, in the whole population (HR: 1.21; 95% CI: 1.04-2.74), and after excluding lung cancer deaths (HR: 1.28; 95% CI: 1.12-1.47). Additionally, we evaluated these associations among people with longer durations of follow-up (9-12 years) from baseline to mortality (n = 7,552). We noted that the detrimental direction of the associations between fasting glucose and cancer mortality persisted among individuals with a longer follow-up, after adjusting for covariates (HR: 1.15; 95% CI: 0.97-1.37). Furthermore, the associations were stronger after exclusion of lung cancer deaths from the analyses (HR: 1.31; 95% CI: 1.11-1.55).
Non-fasting glucose Because previous data have suggested that non-fasting versus fasting glucose concentrations have better predictive value [22] , the associations of non-fasting plasma glucose concentrations in relation to cancer mortality were also evaluated in the present study.
The associations observed for non-fasting glucose were similar to those observed with fasting plasma glucose, with hazard ratios [1 for all cancers combined (HR: 1.18; 95% CI: 1.01-1.19) and after excluding lung cancer (HR: 1.21; 95% CI: 1.03-1.26).
Glycosylated hemoglobin Next, glycosylated hemoglobin was examined in relation to cancer mortality. Glycosylated hemoglobin concentrations were treated as a continuous variable in the regression model. There was a borderline significant 22% increased risk of dying from cancer for 2% increments in this analyte, after adjusting for age only (HR: 1.22; 95% CI: 0.97-1.53) and after adjusting for age, race, physical activity, smoking status, sex, and BMI (HR: 1.22; 95% CI: 0.96-1.55). The detrimental associations persisted when we repeated the analyses after excluding lung cancer We tested for potential interactions between the associations of all the markers of blood glucose metabolism and cancer mortality. However, none of the observed relationships differed by age or sex, and no other significant interactions were noted.
Insulin
We evaluated the associations for four different measures of insulin metabolism in relation to overall cancer mortality and after excluding lung cancer deaths. The age-adjusted risk of dying of all cancers combined was 45% higher among individuals with insulin resistance (HR: 1.45; 95% CI: 1.11-1.89 and 41% higher (HR: 1.41; 95% CI: 1.07-1.87) after adjusting for age, race, physical activity, smoking status, sex, and BMI. These associations were stronger after excluding lung cancer deaths (HR: 1.67; 95% CI: 1.15-2.42) after adjusting for covariates. Furthermore, in order to remove the potential bias of controlled diabetes, we excluded individuals who were either on oral hypoglycemic agent or insulin treatment (n = 949). The associations between insulin resistance and overall cancer mortality persisted (HR: 1.26; 95% CI: 0.90-1.76), and after excluding lung cancer deaths (HR: 1.71; 95% CI: 1.12-2.61).
To investigate whether these associations persisted before a cancer diagnosis, we excluded persons who reported having a history of cancer at baseline. Similar to the results for fasting blood glucose concentrations, the detrimental associations persisted among individuals who were free of cancer at baseline (HR: 1.27; 95% CI: 1.00-1.81) after adjusting for covariates and after excluding lung cancer deaths (HR: 1.60; 95% CI: 1.08-2.36). Next, we reanalyzed these relationships among people with longer durations of follow-up (9-12 years) to mortality (n = 7,606). We noted that the detrimental effect of the associations between fasting glucose and cancer mortality persisted (HR: 1.18; 95% CI: 0.89-1.56) after adjusting for covariates, and was stronger after exclusion of lung cancer deaths from the analyses (HR: 1.80; 95% CI: 1.26-2.56).
To explore whether modest exposure to hyperinsulinemia influences the risk of cancer deaths, the analyses were repeated using the cutoff as 100 mg/dl of plasma glucose (instead of 110 mg/dl), and the risk persisted (HR adjusted for age only: 1.23; 95% CI: 0.95-1.58) and after adjustment of covariates (HR: 1.17 (0.91-1.51)). The risk was stronger after excluding lung cancer deaths in the ageadjusted (HR: 1.39 (1.06-1.82)) and multivariate models (HR: 1.36 (1.00-1.86)).
In this dataset, physical activity was a major risk factor of cancer mortality. Therefore, we explored the relationship of insulin resistance by level of physical activity (above and below median METs). As shown in Table 3 , the HR for cancer mortality was significantly higher among individuals with lower physical activity levels (HR: 1.60; 95% CI: 1.20-2.12), and these associations were stronger after excluding lung cancer deaths (HR: 2.06; 95% CI: 1.41-3.01). It is noteworthy that these associations appeared to be attenuated among individuals with higher physical activity levels, although the effect modification was not statistically significant.
Next, we evaluated cancer mortality in relation to HOMA-IR, plasma insulin, and C-peptide. Although not statistically significant, the HRs for HOMA-IR (HR: 1.06; 95% CI: 0.96-1.13) and C-peptide (HR: 1.05; 95% CI: 0.87-1.28) were [1, consistent with the direction of associations observed for insulin resistance. The associations were similar after excluding lung cancer deaths (HR: 1.05; 95% CI: 0.98-1.14 and HR: 1.15; 95% CI: 0.94-1.41, respectively). No associations were noted between fasting and non-fasting insulin concentrations and cancer mortality (HR: 1.00; 95% CI: 0.97-1.03 and HR: 1.00; 95% CI: 0.99-1.01). No significant interactions were noted for the associations of all markers of insulin metabolism and cancer mortality.
Insulin resistance syndrome
To assess the potential synergistic influence of the obesity, derangements in insulin and glucose metabolism, hypertension, and lipid abnormalities, we evaluated the associations and cancer mortality and the insulin resistance syndrome as per the modified ATP III definition. We noted no associations between the insulin resistance syndrome and cancer mortality for all cancer sites combined (HR: 1.01; 95% CI: 0.72-1.42). Although not statistically significant, the HR for cancer mortality was 16% higher among individuals with the insulin resistance syndrome after excluding lung cancer deaths (HR: 1.16; 95% CI: 0.8-1.67). After excluding persons with self-reported history of cancer at baseline (n = 588), these associations were unchanged (data not shown).
Body mass index
We assessed the associations of cancer mortality and excess adiposity, measured as BMI. Similar to the associations of the insulin resistance syndrome, we noted no associations between BMI (treated as a continuous variable) and mortality from all cancers combined (HR: 0.92; 95% CI: 0.80-1.05), even after excluding lung cancer (HR: 0.96; 95% CI: 0.83-1.11). These associations were reanalyzed using BMI groups as per the WHO classification, and no associations were noted between categories of BMI and cancer mortality in the overall population as well as after excluding lung cancer deaths (data not shown). Additionally, the lack of association persisted after removing individuals with self-reported history of cancer at baseline.
Discussion
Our results using data from the nationally representative NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) survey support the hypothesis that disturbances in insulin and glucose metabolism are associated with an increased risk of cancer mortality. These relationships were stronger after excluding individuals who died of lung cancer, which is a particularly important endpoint because lung cancer is not associated with adiposity in the existing literature [10] . The detrimental effect of the associations persisted after excluding individuals who achieved glycemic control pharmacologically and after excluding individuals with a diagnosis of cancer at baseline, and among individuals with a longer follow-up to mortality of *9-12 years. We observed similar non-significant detrimental associations with higher percentages of glycosylated hemoglobin, a marker of long-term glycemic control. Finally, in exploratory analyses among people who reported high and low levels of physically active, we observed that the risk of overall cancer mortality doubled among individuals who did not engage in at least a moderate level of physical activity.
The results of the current study are consistent with the majority of previous studies that have evaluated diabetes status in relation to cancer mortality. For example, in a large prospective study in the US (n = 467,922 men and 588,321 women), self-reported diabetes was significantly associated with death from multiple cancers in both men and women with risk estimates ranging from 1.20 to 2.19 in multivariate analyses [18] . Similarly, a Japanese population-based study (n = 15,724) reported that having diabetes was associated with an 88% higher risk of dying from all cancers among women [19] . Two other studies found a higher risk of progression and/or death from endometrial cancer [37] and prostate cancer [38] among persons with diabetes versus those without diabetes. Additionally, elevated glycosylated hemoglobin concentrations were associated with poorer 5-year survival for colorectal cancer, and a twofold increased risk of colorectal cancer progression compared to individuals with better glycemic control [16] . It is noteworthy that some of these studies did not have the ability to evaluate markers of plasma glucose or insulin metabolism and relied on self-reported diabetes status [18, 19] .
Not all previous studies reported associations between diabetes and cancer mortality. In a meta-analyses, diabetes was not associated with cancer mortality (p = 0.69) [39] . However, this study did not evaluate insulin resistance and restricted analyses to diabetes status in existing patients. Similarly, another study did not observe any differences between cancer mortality rates in people with diabetes versus those without diabetes, which was confirmed from medical records [17] . Our report of increased risk of cancer mortality among insulin-resistant individuals adds to the limited existing evidence noting similar detrimental associations. There is robust evidence from two large prospective studies suggesting 50% to a threefold increased risk of mortality from colorectal cancer among participants with insulin resistance or associated biochemical abnormalities after adjusting for covariates [20, 22] . In a prospective cohort study evaluating the late effects of cancer among 512 women with breast cancer, insulin resistance was associated with an approximately threefold increased risk of death from the disease after adjusting for tumor-and treatment-related variables [21] . Similarly, in a 10-year prospective Korean study (n = 1,298,385), individuals with higher versus lower fasting serum glucose concentrations (proxy for insulin resistance) were *30% more likely to die of cancer (all cancers combined), and these detrimental associations persisted across all body mass index categories, suggesting an independent role of insulin beyond excess body weight [15] .
Several biological mechanisms might explain the observed relationships between disturbed insulin and glucose metabolism and cancer mortality in the current study. It has been well documented that glucose increases cancer cell growth, with upregulation of cell proliferation factors and delayed apoptosis [40] [41] [42] . Insulin resistance, characterized by higher circulating levels of insulin, is associated with poor glycemic control. Insulin is an anabolic hormone that may stimulate cell proliferation and cancer progression via multiple pathways by increasing production of IGF-1 via the growth hormone mechanism (reviewed in [43, 44] ) making more IGF-1 available to bind to its receptors on normal and cancer cells. This receptor-bound IGF-1 modulates cell proliferation and survival (reviewed in [43] and [44] ). Normally, insulin stimulates liver uptake of glucose and the storage of glucose as glycogen or enhances its metabolism via the glycolytic pathway. However, insulin fails to suppress gluconeogenesis in laboratory studies [45] , implying further glucose availability for cellular metabolism of cancer cells. Another factor common to insulin resistance, hyperglycemia, and cancer is inflammation [46] [47] [48] [49] [50] [51] . An increase in pro-inflammatory factors produces a cellular environment, which makes it conducive to oncogenesis, cancer progression, and mortality [51] . In fact one study has reported modest increased risk of cancer mortality among subjects with joint exposure to inflammation and obesity, a proxy for disturbances in insulin metabolism [48] .
Despite the potential biological mechanisms of insulin in cancer biology, associations were either not observed or were not significant for HOMA-IR, fasting C-peptide and fasting insulin concentrations, and overall cancer mortality, or after excluding cases of lung cancer deaths in this study. Previous studies investigating cancer risk or mortality have shown the limited predictive value of fasting concentrations biomarkers of the insulin-glucose axis and reported associations that were limited to plasma obtained in a non-fasting state [52, 53] . One study investigating risk of colon cancer observed similar findings for C-peptide [54] , suggesting that postprandial insulin may be a better measure for the association with cancer risk than fasting insulin levels. We speculate that this might be one explanation for the lack of associations observed for some of the markers of insulin metabolism, in this sample. Based on the findings of previous studies that suggest that non-fasting values are more appropriate choices, we also performed analyses in the current study sample using non-fasting insulin and C-peptide values. However, we did not have sufficient power to detect these associations if they did exist, because the measurements of non-fasting insulin and C-peptide were done in a subsample of individuals aged 40-74 among those who participated in the study in the second phase of NHANES III (n = 3,747; *20% of the total sample eligible for this study).
Finally, the insulin resistance syndrome was not associated with cancer mortality. This may be explained by the fact that insulin resistance syndrome comprises of 3-5 components, which may negate the effects of the independent component, suggesting that the confluence of these factors is not important in cancer deaths. However, nonsignificant detrimental associations were observed after excluding lung cancer among people with versus without insulin resistance syndrome and warrant further exploration. One previous large study using the Chicago Heart Association Detection Project in Industry population reported a 50% increased risk of colon cancer mortality among participants having the insulin resistance syndrome (C3 of 5 biochemical abnormalities) [22] . Another large study among men reported a 56% greater risk of death from all cancers combined among individuals with metabolic syndrome [23] . Similarly, an approximate threefold increased risk of colorectal cancer mortality was observed in one study among men and women with metabolic syndrome [20] . However, they speculated that elevated blood glucose might be the component ''driving'' the associations [20] .
Differently from previous studies that report associations between BMI and cancer deaths [10, 55] , we did not observe any associations between increased BMI or waist circumference and overall cancer mortality in the whole population or after excluding individuals who died of lung cancer. We explored these relationships separately by sex to check for gender differences; however, the associations were null. It is not uncommon to have shifts in body composition among those who develop cancer. Lack of information of BMI status after recruitment at baseline among the cancer patients and the inability to adjust for this may be a potential explanation for the null findings, although we were not able to identify a definitive explanation for these results.
Some weaknesses of this study must be noted. Due to a limited number of cancer deaths, we did not have the ability to evaluate site-specific cancers in relation to markers of insulin and glucose metabolism. Although, cancer deaths ascertained from death certificates agree well with cause of death from autopsies, there could be potential misclassification of the underlying cause of death on the death certificates, which were used to ascertain diseasespecific mortality. Evidence suggests that this type of misclassification may attenuate the observed relationships [56] . However, studies have been published using NHANES III mortality data [57, 58] . Cancer mortality was ascertained longitudinally in NHANES III, but there was only one measure of the exposures of interest, taken *8.5 years before mortality follow-up, causing potential bias toward the null. This single measurement would likely attenuate any associations as it fails to detect new individuals who may have developed insulin resistance in the follow-up period and does not account for individuals who may have made lifestyle changes to improve their glycemic profile. Finally, the results of this study might be an underestimation of the problem, because the exposure data were collected in 1988-1994, and obesity and diabetes rates have increased in the past two decades [59, 60] .
In conclusion, the results from this large longitudinal nationally representative study add to the existing epidemiologic evidence that hyperglycemia and insulin resistance may increase the risk of cancer morality. With the rising number of cancer survivors in the US and projected doubling by 2050 [3] , as well as increasing prevalence of insulin resistance and diabetes, it is the time to consider management of these modifiable risk factors, through healthier lifestyles, specifically physical activity as an important cancer control tool. The body of existing evidence and the current study support a need for updated clinical guidelines among the very large at-risk population of cancer patients to prevent disease-specific mortality. The findings of this research support designing lifestyle intervention trials aimed at the eventual development of individualized treatment, and support the management of disturbances of the glucose-insulin axis for cancer control.
